title: Filgrastim (r-metHuG-CSF) in the 21st century: SD/01.
abstract: SD/01, a sustained-duration molecule, has been developed by adding a poly [ethylene glycol] molecule to the filgrastim molecule. The pegylation does not change the properties of filgrastim, except that the plasma clearance is decreased and plasma half-life is increased. Increasing the duration of the biological effects of filgrastim may offer certain groups of patients better benefits. Early clinical studies have been encouraging with no serious toxicities noted.
authors.affiliation: Amgen Inc., Thousand Oaks, CA 91230-1799, USA. gmorstyn@amgen.com
authors.forename: G
authors.initials: G
authors.lastname: Morstyn
authors.forename: M A
authors.initials: MA
authors.lastname: Foote
authors.forename: T
authors.initials: T
authors.lastname: Walker
authors.forename: G
authors.initials: G
authors.lastname: Molineux
mesh_terms: D000818:Animals; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006801:Humans; D009503:Neutropenia / Q000188:drug therapy; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; C414042:SD-01 recombinant; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim